A new market research report on the Global Head & Neck Cancer Drugs market has introduced by KD Market Insights. The report is dedicated to in-depth industry analysis of the global Head & Neck Cancer Drugs market. The Global Head & Neck Cancer Drugs analysis is broken down on different segmentation levels including Market By Drug Class, By Sales Channel.
The global head & neck cancer drugs market was valued at $1,295 million in 2017, and is projected to reach $2,281 million by 2025, registering a CAGR of 7.3% from 2018 to 2025. Head & neck cancers include a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses, lips, salivary glands and mouth. Head and neck squamous cell carcinoma (HNSCC) is the most common form of head & neck cancer, which develops in the mucous membranes of the mouth, nose, and throat. Chemotherapy, immunotherapy & targeted therapy are used for the treatment of head & neck cancer along with the radiation & surgical procedures.
Get Report Sample Copy @ https://www.kdmarketinsights.com/sample/3391
There is an increase in the demand for head & neck cancer drugs owing to the growth in incidence of head & neck cancer, rise in demand for combination therapeutics, higher number of R&D studies, and surge in adoption of immune therapeutics. In addition, growth in the geriatric population and technological advancements in screening & diagnosis of head & neck cancer further drive the market growth. Strong presence of late-stage pipeline drugs such as Ipilimumab, Atezolizumab, Avelumab, Durvalumab, Erlotinib, Afatinib, Bevacizumab, and others are expected to drive the market growth. However, higher cost & adverse effect associated with head & neck cancer drugs are projected to impede the market growth.
The global head & neck cancer drugs market is segmented based on drug class, sales channel, and region. Based on drug class, the market is classified as chemotherapy, immunotherapy, and targeted therapy. According to the sales channel, the market is categorized as hospital pharmacies, drug stores and retail pharmacies, and online stores. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and rest of LAMEA).
Key Benefits for Head & Neck Cancer Drugs Market:
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
Head & Neck Cancer Drugs Key Market Segments:
By Drug Class
- Chemotherapy
- Immunotherapy
- Targeted Therapy
By Sales Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Stores
By Region
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
List of Key Players Profiled in the Report:
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Eli Lilly and Company (ARMO Biosciences.)
- Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)
- F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
- Immutep Limited
- Merck & Co., Inc.
- Merck KGaA (EMD Serono, Inc.)
- Novartis AG
- Pfizer Inc.
Access Complete Research Report with TOC @ https://www.kdmarketinsights.com/product/head-and-neck-cancer-drugs-market-amr
Table of Content
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top player positioning
3.3. MARKET DYNAMICS
3.3.1. Drivers
3.3.1.1. Surge in incidence of head and neck cancer worldwide
3.3.1.2. Surge in global geriatric population
3.3.1.3. Increase in consumption of tobacco and alcohol
3.3.2. Restraints
3.3.2.1. Adverse effects associated with the use of head and neck cancer drugs
3.3.3. Opportunities
3.3.3.1. Untapped emerging economies
3.3.3.2. Increase in number of pipeline drugs
3.3.4. Impact Analyses
CHAPTER 4: HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Chemotherapy
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Immunotherapy
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Targeted therapy
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
CHAPTER 5: HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospital pharmacy
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Online providers
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Drug stores & retail pharmacies
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6: HEAD & NECK CANCER DRUGS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. head & neck cancer drugs market, by drug class
6.2.2.1.2. U.S. head & neck cancer drugs market, by sales channel
6.2.2.2. Canada
6.2.2.2.1. Canada head & neck cancer drugs market, by drug class
6.2.2.2.2. Canada head & neck cancer drugs market, by sales channel
6.2.2.3. Mexico
6.2.2.3.1. Mexico head & neck cancer drugs market, by drug class
6.2.2.3.2. Mexico head & neck cancer drugs market, by sales channel
6.2.3. North America market size and forecast, by drug class
6.2.4. North America market size and forecast, by sales channel
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Germany head & neck cancer drugs market, by drug class
6.3.2.1.2. Germany head & neck cancer drugs market, by sales channel
6.3.2.2. France
6.3.2.2.1. France head & neck cancer drugs market, by drug class
6.3.2.2.2. France head & neck cancer drugs market, by sales channel
6.3.2.3. UK
6.3.2.3.1. UK head & neck cancer drugs market, by drug class
6.3.2.3.2. UK head & neck cancer drugs market, by sales channel
6.3.2.4. Italy
6.3.2.4.1. Italy head & neck cancer drugs market, by drug class
6.3.2.4.2. Italy head & neck cancer drugs market, by sales channel
6.3.2.5. Spain
6.3.2.5.1. Spain head & neck cancer drugs market, by drug class
6.3.2.5.2. Spain head & neck cancer drugs market, by sales channel
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe head & neck cancer drugs market, by drug class
6.3.2.6.2. Rest of Europe head & neck cancer drugs market, by sales channel
6.3.3. Europe market size and forecast, by drug class
6.3.4. Europe market size and forecast, by sales channel
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan head & neck cancer drugs market, by drug class
6.4.2.1.2. Japan head & neck cancer drugs market, by sales channel
Continue @...
Check for Discount @ https://www.kdmarketinsights.com/discount/3391
About Us:
KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.
Contact Us:
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: http://www.kdmarketinsights.com
Read More:
https://pr-wire.blogspot.com/
https://dailyprpost.blogspot.com/
http://umarketresearch.com
The global head & neck cancer drugs market was valued at $1,295 million in 2017, and is projected to reach $2,281 million by 2025, registering a CAGR of 7.3% from 2018 to 2025. Head & neck cancers include a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses, lips, salivary glands and mouth. Head and neck squamous cell carcinoma (HNSCC) is the most common form of head & neck cancer, which develops in the mucous membranes of the mouth, nose, and throat. Chemotherapy, immunotherapy & targeted therapy are used for the treatment of head & neck cancer along with the radiation & surgical procedures.
Get Report Sample Copy @ https://www.kdmarketinsights.com/sample/3391
There is an increase in the demand for head & neck cancer drugs owing to the growth in incidence of head & neck cancer, rise in demand for combination therapeutics, higher number of R&D studies, and surge in adoption of immune therapeutics. In addition, growth in the geriatric population and technological advancements in screening & diagnosis of head & neck cancer further drive the market growth. Strong presence of late-stage pipeline drugs such as Ipilimumab, Atezolizumab, Avelumab, Durvalumab, Erlotinib, Afatinib, Bevacizumab, and others are expected to drive the market growth. However, higher cost & adverse effect associated with head & neck cancer drugs are projected to impede the market growth.
The global head & neck cancer drugs market is segmented based on drug class, sales channel, and region. Based on drug class, the market is classified as chemotherapy, immunotherapy, and targeted therapy. According to the sales channel, the market is categorized as hospital pharmacies, drug stores and retail pharmacies, and online stores. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and rest of LAMEA).
Key Benefits for Head & Neck Cancer Drugs Market:
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
Head & Neck Cancer Drugs Key Market Segments:
By Drug Class
- Chemotherapy
- Immunotherapy
- Targeted Therapy
By Sales Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Stores
By Region
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
List of Key Players Profiled in the Report:
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Eli Lilly and Company (ARMO Biosciences.)
- Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)
- F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
- Immutep Limited
- Merck & Co., Inc.
- Merck KGaA (EMD Serono, Inc.)
- Novartis AG
- Pfizer Inc.
Access Complete Research Report with TOC @ https://www.kdmarketinsights.com/product/head-and-neck-cancer-drugs-market-amr
Table of Content
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top player positioning
3.3. MARKET DYNAMICS
3.3.1. Drivers
3.3.1.1. Surge in incidence of head and neck cancer worldwide
3.3.1.2. Surge in global geriatric population
3.3.1.3. Increase in consumption of tobacco and alcohol
3.3.2. Restraints
3.3.2.1. Adverse effects associated with the use of head and neck cancer drugs
3.3.3. Opportunities
3.3.3.1. Untapped emerging economies
3.3.3.2. Increase in number of pipeline drugs
3.3.4. Impact Analyses
CHAPTER 4: HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Chemotherapy
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Immunotherapy
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Targeted therapy
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
CHAPTER 5: HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospital pharmacy
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Online providers
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Drug stores & retail pharmacies
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6: HEAD & NECK CANCER DRUGS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. head & neck cancer drugs market, by drug class
6.2.2.1.2. U.S. head & neck cancer drugs market, by sales channel
6.2.2.2. Canada
6.2.2.2.1. Canada head & neck cancer drugs market, by drug class
6.2.2.2.2. Canada head & neck cancer drugs market, by sales channel
6.2.2.3. Mexico
6.2.2.3.1. Mexico head & neck cancer drugs market, by drug class
6.2.2.3.2. Mexico head & neck cancer drugs market, by sales channel
6.2.3. North America market size and forecast, by drug class
6.2.4. North America market size and forecast, by sales channel
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Germany head & neck cancer drugs market, by drug class
6.3.2.1.2. Germany head & neck cancer drugs market, by sales channel
6.3.2.2. France
6.3.2.2.1. France head & neck cancer drugs market, by drug class
6.3.2.2.2. France head & neck cancer drugs market, by sales channel
6.3.2.3. UK
6.3.2.3.1. UK head & neck cancer drugs market, by drug class
6.3.2.3.2. UK head & neck cancer drugs market, by sales channel
6.3.2.4. Italy
6.3.2.4.1. Italy head & neck cancer drugs market, by drug class
6.3.2.4.2. Italy head & neck cancer drugs market, by sales channel
6.3.2.5. Spain
6.3.2.5.1. Spain head & neck cancer drugs market, by drug class
6.3.2.5.2. Spain head & neck cancer drugs market, by sales channel
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe head & neck cancer drugs market, by drug class
6.3.2.6.2. Rest of Europe head & neck cancer drugs market, by sales channel
6.3.3. Europe market size and forecast, by drug class
6.3.4. Europe market size and forecast, by sales channel
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan head & neck cancer drugs market, by drug class
6.4.2.1.2. Japan head & neck cancer drugs market, by sales channel
Continue @...
Check for Discount @ https://www.kdmarketinsights.com/discount/3391
About Us:
KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.
Contact Us:
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: http://www.kdmarketinsights.com
Read More:
https://pr-wire.blogspot.com/
https://dailyprpost.blogspot.com/
http://umarketresearch.com
No comments:
Post a Comment